Appetite hormone CART helps increase insulin secretion, reduce glucagon production

NewsGuard 100/100 Score

The study shows that the appetite hormone CART not only controls the sensation of satiety, but it also helps increase insulin secretion and decrease glucagon production.

CART (Cocaine and Amphetamine-Regulated Transcript) is a hormone that has mainly been studied in the brain's centre for appetite control.

The research group behind the new study made the previously unknown discovery that CART can also be found in human alpha and beta cells located in the pancreas, and that cells from people with type 2 diabetes contain more CART than cells in people who are healthy.

"The high glucose levels could be what triggers the production of CART", says Nils Wierup.

The study also shows that CART increases the effect of GLP-1, an intestinal hormone that lowers blood sugar levels. GLP-1 represents the basis of the latest drugs against type 2 diabetes by stimulating the body's own insulin production.

Nils Wierup says that the new discoveries can eventually lead to new drugs against type 2 diabetes. However, because CART is currently only available for research purposes, the active molecule of the hormone needs to be further developed to create the equivalent effect artificially. Furthermore, the receptor that binds to the molecule is still unknown.

"However, we believe that we're getting close", says Nils Wierup and continues: "Once we find the unknown receptor, we hope to explain the biological mechanisms behind CART's function, which will hopefully lead to new and better drugs."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancer